BillionToOne, Inc.
BillionToOne (BLLN) CEO Oguzhan Atay sold 30,331 shares for $3M on Sept 14, 2026, per SEC filing. The sale included cash-less option exercises and shares from his spouse's account, executed under a pre-planned trading plan. Atay retains 501,962 vested options and his spouse holds 157,168 shares. BLLN reported $109.4M Q2 2026 revenue, up 64% YoY, and forecasts $450M-$465M for full-year 2026.
Atay Oguzhan (Chairman and CEO) sold 5,332 indirectly-held shares of BillionToOne, Inc. (BLLN) at $98.00 ($0.52M total) across 2 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
Atay Oguzhan (Chairman and CEO) sold 24,999 shares of BillionToOne, Inc. (BLLN) at an average of $100.32 ($98.63–$101.49, $2.51M total) across 8 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BLLN (BillionToOne, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent BLLN coverage spans insider activity, financial news and technology.
In the last 30 days, BLLN insiders filed 28 SEC Form 4 transactions — no purchases and 28 sales ($8.3M). The most active reporter was Lynch Thomas P., See Remarks, with 13 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may weigh on sentiment and create modest short‑term selling pressure.
Insider sale may signal confidence concerns, but size is modest relative to float.
Insider sell may signal weak confidence, creating slight downside pressure.
The insider sale may signal limited confidence from the CTO, potentially exerting slight downward pressure on the stock.
Insider sale may signal lack of confidence, but size is modest relative to market cap.
AlphAI scores every news story that mentions BLLN with an AI model for sentiment and relevance, and aggregates insider trades from BillionToOne, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BillionToOne (BLLN) CEO Oguzhan Atay sold 30,331 shares for $3M on Sept 14, 2026, per SEC filing. The sale included cash-less option exercises and shares from his spouse's account, executed under a pre-planned trading plan. Atay retains 501,962 vested options and his spouse holds 157,168 shares. BLLN reported $109.4M Q2 2026 revenue, up 64% YoY, and forecasts $450M-$465M for full-year 2026.
2 min readAtay Oguzhan (Chairman and CEO) sold 5,332 indirectly-held shares of BillionToOne, Inc. (BLLN) at $98.00 ($0.52M total) across 2 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readAtay Oguzhan (Chairman and CEO) sold 24,999 shares of BillionToOne, Inc. (BLLN) at an average of $100.32 ($98.63–$101.49, $2.51M total) across 8 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readTsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $98.77 ($97.54–$100.00, $1.98M total) across 2 trades on 2026-09-09 under a Rule 10b5-1 trading plan.
1 min readLynch Thomas P. (See Remarks) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $99.99 ($96.47–$101.41, $2.00M total) across 13 trades on 2026-09-08 under a Rule 10b5-1 trading plan.
1 min readTsao David (Chief Technology Officer) sold 10,000 shares of BillionToOne, Inc. (BLLN) at $100.00 ($1.00M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readBillionToOne (BLLN) published a study in The Green Journal showing its Unity Fetal Risk Screen, a cfDNA-based test, demonstrated 94.4% sensitivity, 99.5% specificity, and >99.9% negative predictive value in assessing fetal risk for recessive conditions in 2,212 general-risk pregnancies. The study, conducted across nine U.S. institutions, supports the use of cfDNA fetal risk assessment as a primary screen in routine prenatal care, offering advantages over traditional carrier screening.
2 min readTsao David (Chief Technology Officer) sold 10,000 shares of BillionToOne, Inc. (BLLN) at $92.86 ($0.93M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
2 min readBTIG named BillionToOne (BLLN) its top diagnostics pick, reiterating a Buy rating while lowering its price target to $130 from $142. BTIG cited Q2 FY2026 revenue of $109.4M, up 64% YoY, and prenatal volumes of about 181,000. Shares fell 28% after-hours. BTIG noted lower true-ups and a payor-related item, and kept FY2026 guidance at $450M to $465M.
3 min readAtay Oguzhan (Chairman and CEO) sold 15,539 shares of BillionToOne, Inc. (BLLN) at $150.03 ($2.33M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min read
